| Year |
Title |
Altmetric |
| 2021
|
Targeting the HuR oncogenic role with a new class of cytoplasmic dimerization inhibitors.
Cancer Research.
81:2220-2233.
2021
|
|
| 2021
|
Human gut microbial communities dictate efficacy of anti-PD-1 therapy in a humanized microbiome mouse model of glioma.
2021
|
|
| 2020
|
Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy.
Nature Communications.
11.
2020
|
|
| 2020
|
Mapping uncharted territory: A gene expression signature for precision glioblastoma therapeutics.
Neuro-Oncology.
22:1713-1714.
2020
|
|
| 2020
|
Central nervous system cancers, version 3.2020
2020
|
|
| 2020
|
Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: Conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.
Neuro-Oncology.
22:1422-1424.
2020
|
|
| 2020
|
Elavl1 role in cell fusion and tunneling membrane nanotube formations with implication to treat glioma heterogeneity.
Cancers.
12:1-18.
2020
|
|
| 2020
|
Seven-Year Experience from the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.
JAMA Neurology.
77:755-763.
2020
|
|
| 2020
|
A troublesome burden, the amplification of EGFR in glioblastoma!.
Neuro-Oncology.
22:594-595.
2020
|
|
| 2020
|
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Neuro-Oncology.
22:601-612.
2020
|
|
| 2020
|
Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (REACT): Results of a double-blind randomized phase II trial.
Clinical Cancer Research.
26:1586-1594.
2020
|
|
| 2020
|
Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.
International Journal of Cancer.
146:739-748.
2020
|
|
| 2020
|
An update on neurofibromatosis type 1-associated gliomas.
Cancers.
12.
2020
|
|
| 2019
|
Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma.
Scientific Reports.
9.
2019
|
|
| 2019
|
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.
Neuro-Oncology.
21:1498-1508.
2019
|
|
| 2019
|
Letter: When less is more: Dexamethasone dosing for brain tumors.
Neurosurgery.
85:E607-E608.
2019
|
|
| 2019
|
Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells.
Cancer Biology and Therapy.
20:979-988.
2019
|
|
| 2019
|
Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.
PLoS Medicine.
16.
2019
|
|
| 2019
|
Highlights of the inaugural ten - the launch of Neuro-Oncology Advances.
2019
|
|
| 2019
|
Management of Central Nervous System Tumors
2019
|
|
| 2019
|
An early feasibility study of the Nativis Voyager ® device in patients with recurrent glioblastoma: first cohort in US.
CNS Oncology.
8:CNS30.
2019
|
|
| 2019
|
Individualized screening trial of innovative glioblastoma therapy (INSIGhT): A Bayesian adaptive platform trial to develop precision medicines for patients with glioblastoma
2019
|
|
| 2019
|
MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trials.
Clinical Cancer Research.
25:1809-1816.
2019
|
|
| 2019
|
Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma..
Clinical Cancer Research.
25:73-79.
2019
|
|
| 2019
|
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR -amplified, recurrent glioblastoma: Results from an international phase I multicenter trial.
Neuro-Oncology.
21:106-114.
2019
|
|
| 2018
|
Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM).
Annals of Oncology.
29:viii122-viii123.
2018
|
|
| 2018
|
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
European journal of cancer.
101:95-104.
2018
|
|
| 2018
|
Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma
2018
|
|
| 2018
|
Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma.
Cancer Research.
78:3002-3013.
2018
|
|
| 2018
|
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?.
Journal of Neuro-Oncology.
138:163-171.
2018
|
|
| 2018
|
Handedness and the risk of glioma.
Journal of Neuro-Oncology.
137:639-644.
2018
|
|
| 2018
|
Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment..
Journal of Cancer Science and Therapy.
10:190-197.
2018
|
|
| 2017
|
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Cancer Chemotherapy and Pharmacology.
80:1209-1217.
2017
|
|
| 2017
|
The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy.
Neurocase.
23:287-291.
2017
|
|
| 2017
|
Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelines
2017
|
|
| 2017
|
Hu antigen R (HuR) multimerization contributes to glioma disease progression.
Journal of Biological Chemistry.
292:16999-17010.
2017
|
|
| 2017
|
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
2017
|
|
| 2017
|
Implementation and utilization of the molecular tumor board to guide precision medicine..
Oncotarget.
8:57845-57854.
2017
|
|
| 2017
|
When less is better: Care of the elderly with glioblastoma.
Neuro-Oncology.
19:879.
2017
|
|
| 2017
|
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Neuro-Oncology.
19:845-852.
2017
|
|
| 2017
|
Older age at the completion of linear growth is associated with an increased risk of adult glioma.
Cancer Causes and Control.
1-8.
2017
|
|
| 2017
|
Repeatability of 18F-FLT PET in a multicenter study of patients with high-grade glioma.
Journal of Nuclear Medicine.
58:393-398.
2017
|
|
| 2017
|
Implementation and utilization of the molecular tumor board to guide precision medicine.
Oncotarget.
8:57845-57854.
2017
|
|
| 2016
|
Primary Sellar Rhabdomyosarcoma Arising in Association with a Pituitary Adenoma.
International Journal of Surgical Pathology.
24:753-756.
2016
|
|
| 2016
|
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM).
Annals of Oncology.
27:vi103.
2016
|
|
| 2016
|
Analgesic use and the risk of primary adult brain tumor.
European Journal of Epidemiology.
31:917-925.
2016
|
|
| 2016
|
Reply to F. Felix et al and M.F. Fay et al.
Journal of Clinical Oncology.
34:3107-3108.
2016
|
|
| 2016
|
Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma Multiforme
2016
|
|
| 2016
|
Design of a Phase i Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
2016
|
|
| 2016
|
Central nervous system: Notable developments in the management of primary and recurrent gliomas
2016
|
|
| 2016
|
Cilengitide in newly diagnosed glioblastoma: Biomarker expression and outcome.
Oncotarget.
7:15018-15032.
2016
|
|
| 2016
|
Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma.
Journal of Clinical Oncology.
34:731-739.
2016
|
|
| 2016
|
Complications from pharmacotherapy.
Handbook of Clinical Neurology.
134:235-250.
2016
|
|
| 2015
|
Capacity of patients with brain metastases to make treatment decisions
2015
|
|
| 2015
|
Central Nervous System Cancers, Version 1.2015.
2015
|
|
| 2015
|
Central nervous system cancers, version 1.2015: Featured updates to the NCCN guidelines
2015
|
|
| 2015
|
Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors.
Journal of Clinical Oncology.
33:3186-3192.
2015
|
|
| 2015
|
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.
Journal of Neuro-Oncology.
125:123-131.
2015
|
|
| 2015
|
Complementary therapy and survival in glioblastoma
2015
|
|
| 2015
|
Cognitive Predictors of Reasoning through Treatment Decisions in Patients with Newly Diagnosed Brain Metastases.
Journal of the International Neuropsychological Society.
21:412-418.
2015
|
|
| 2015
|
Ipilimumab-induced encephalopathy with a reversible splenial lesion.
Cancer Immunology Research.
3:598-601.
2015
|
|
| 2015
|
Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.
Journal of Neuro-Oncology.
122:585-593.
2015
|
|
| 2015
|
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: Results of the open-label, controlled, randomized phase II CORE study.
Neuro-Oncology.
17:708-717.
2015
|
|
| 2015
|
Growth factor dependent regulation of centrosome function and genomic instability by HuR.
Biomolecules.
5:263-281.
2015
|
|
| 2015
|
Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumor
2015
|
|
| 2015
|
Brain tumor risk according to germ-line variation in the MLLT10 locus.
European Journal of Human Genetics.
23:132-134.
2015
|
|
| 2015
|
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Neuro-Oncology.
17:430-439.
2015
|
|
| 2015
|
SLC7A1 expression is associated with seizures, predicts poor survival in patients with malignant glioma.
Science Translational Medicine.
7.
2015
|
|
| 2014
|
Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: The University of Alabama at Birmingham experience
2014
|
|
| 2014
|
Central nervous system cancers, Version 2.2014: Featured updates to the NCCN guidelines
2014
|
|
| 2014
|
Role of MRI in primary brain tumor evaluation
2014
|
|
| 2014
|
Cognition in patients with newly diagnosed brain metastasis: Profiles and implications.
Journal of Neuro-Oncology.
120:179-185.
2014
|
|
| 2014
|
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
2014
|
|
| 2014
|
The role of bevacizumab in glioblastoma
2014
|
|
| 2014
|
A phase 1 trial of oncolytic HSV-1, g207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.
Molecular Therapy.
22:1048-1055.
2014
|
|
| 2014
|
Circadian pathway genes in relation to glioma risk and outcome.
Cancer Causes and Control.
25:25-32.
2014
|
|
| 2014
|
Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.
Journal of Neuro-Oncology.
118:61-72.
2014
|
|
| 2014
|
Reproductive factors and risk of primary brain tumors in women.
Journal of Neuro-Oncology.
118:297-304.
2014
|
|
| 2014
|
Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
Journal of Neuro-Oncology.
120:361-370.
2014
|
|
| 2014
|
The role of Src family kinases in growth and migration of glioma stem cells.
International Journal of Oncology.
45:302-310.
2014
|
|
| 2013
|
Toenail iron, genetic determinants of iron status, and the risk of glioma.
Cancer Causes and Control.
24:2051-2058.
2013
|
|
| 2013
|
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Journal of Clinical Oncology.
31:3212-3218.
2013
|
|
| 2013
|
Central nervous system cancers
2013
|
|
| 2013
|
Early life exposures and the risk of adult glioma.
European Journal of Epidemiology.
28:753-758.
2013
|
|
| 2013
|
Prediagnostic body weight and survival in high grade glioma.
Journal of Neuro-Oncology.
114:79-84.
2013
|
|
| 2013
|
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study..
Journal of Clinical Oncology.
31:LBA2009.
2013
|
|
| 2013
|
Mutant tristetraprolin: A potent inhibitor of malignant glioma cell growth.
Journal of Neuro-Oncology.
113:195-205.
2013
|
|
| 2013
|
Anthropometric factors in relation to risk of glioma.
Cancer Causes and Control.
24:1025-1031.
2013
|
|
| 2013
|
NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Neuro-Oncology.
15:490-496.
2013
|
|
| 2013
|
SWI/SNF gene variants and glioma risk and outcome
2013
|
|
| 2013
|
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Clinical Cancer Research.
19:900-908.
2013
|
|
| 2012
|
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Cancer.
118:5601-5607.
2012
|
|
| 2012
|
Erratum: An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome (Cancer Causes Control DOI:10.1007/s10552-012-0018-7).
Cancer Causes and Control.
23:1745.
2012
|
|
| 2012
|
Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome function.
Journal of Biological Chemistry.
287:32277-32287.
2012
|
|
| 2012
|
Primary central nervous system angiosarcoma: Two case reports.
Journal of Medical Case Reports.
6.
2012
|
|
| 2012
|
Rare TP53 genetic variant associated with glioma risk and outcome.
Journal of Medical Genetics.
49:420-421.
2012
|
|
| 2012
|
SSBP2 variants are associated with survival in glioblastoma patients.
Clinical Cancer Research.
18:3154-3162.
2012
|
|
| 2012
|
Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuR.
Journal of Neuroimmunology.
246:34-37.
2012
|
|
| 2012
|
An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome.
Cancer Causes and Control.
23:1443-1449.
2012
|
|
| 2011
|
A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma.
Journal of Neuro-Oncology.
105:639-646.
2011
|
|
| 2011
|
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
Neuro-Oncology.
13:1324-1330.
2011
|
|
| 2011
|
Phase i and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.
Journal of Neuro-Oncology.
105:375-381.
2011
|
|
| 2011
|
Erratum: Cancer susceptibility variants and the risk of adult glioma in a US case-control study (Journal of Neuro-Oncology DOI: 10.1007/s11060-010-0506-0).
Journal of Neuro-Oncology.
104:543.
2011
|
|
| 2011
|
A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma..
Journal of Clinical Oncology.
29:2010.
2011
|
|
| 2011
|
The RNA-binding protein HuR promotes glioma growth and treatment resistance
2011
|
|
| 2011
|
Central nervous system cancers: Clinical practice guidelines in oncology
2011
|
|
| 2011
|
Cilengitide: An RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
Future Oncology.
7:339-354.
2011
|
|
| 2011
|
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide
2011
|
|
| 2011
|
Cancer susceptibility variants and the risk of adult glioma in a US case-control study.
Journal of Neuro-Oncology.
104:535-542.
2011
|
|
| 2010
|
Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients
2010
|
|
| 2010
|
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
Journal of Neuro-Oncology.
100:95-103.
2010
|
|
| 2010
|
Integrins-a relevant target in glioblastoma.
European journal of clinical & medical oncology.
2.
2010
|
|
| 2010
|
Targeting integrins in malignant glioma.
Targeted Oncology.
5:175-181.
2010
|
|
| 2010
|
Capacity to consent to research participation in adults with malignant glioma.
Journal of Clinical Oncology.
28:3844-3850.
2010
|
|
| 2010
|
Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.
Clinical Cancer Research.
16:2890-2898.
2010
|
|
| 2010
|
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Clinical Cancer Research.
16:2443-2449.
2010
|
|
| 2010
|
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Archives of Neurology.
67:313-319.
2010
|
|
| 2009
|
Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR). Implications for impaired post-transcriptional regulation of vascular endothelial growth factor.
Journal of Biological Chemistry.
284:33989-33998.
2009
|
|
| 2009
|
Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma.
Neuro-Oncology.
11:357-367.
2009
|
|
| 2009
|
Distress and quality of life in primary high-grade brain tumor patients.
Supportive Care in Cancer.
17:793-799.
2009
|
|
| 2009
|
Will integrin inhibitors have proangiogenic effects in the clinic?.
Nature Medicine.
15:726.
2009
|
|
| 2009
|
A phase I evaluation of intravenous (IV) (131)I-chlorotoxin delivery to solid peripheral and intracranial tumors..
Journal of Clinical Oncology.
27:e14507.
2009
|
|
| 2009
|
A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects..
Journal of Clinical Oncology.
27:2041.
2009
|
|
| 2009
|
A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme..
Journal of Clinical Oncology.
27:2023.
2009
|
|
| 2009
|
Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States..
Journal of Clinical Oncology.
27:2003.
2009
|
|
| 2009
|
Dosimetry study of a phase II multiple-dose intracavitary administration of (131)I-TM601 in adult patients with recurrent high-grade glioma..
Journal of Clinical Oncology.
27:e13006.
2009
|
|
| 2009
|
Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma..
Journal of Clinical Oncology.
27:2039.
2009
|
|
| 2009
|
NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM)..
Journal of Clinical Oncology.
27:2001.
2009
|
|
| 2009
|
NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM)..
Journal of Clinical Oncology.
27:2010.
2009
|
|
| 2009
|
Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results..
Journal of Clinical Oncology.
27:2042.
2009
|
|
| 2009
|
Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate.
American Journal of Transplantation.
9:1243-1248.
2009
|
|
| 2009
|
High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI.
Magnetic Resonance in Medicine.
61:615-625.
2009
|
|
| 2009
|
Medical decision-making capacity in patients with malignant glioma.
Neurology.
73:2086-2092.
2009
|
|
| 2009
|
Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
Molecular Therapy.
17:199-207.
2009
|
|
| 2008
|
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
Journal of Clinical Oncology.
26:5610-5617.
2008
|
|
| 2008
|
The ING4 tumor suppressor attenuates NF-κB activity at the promoters of target genes.
Molecular and Cellular Biology.
28:6632-6645.
2008
|
|
| 2008
|
Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Expert Opinion on Investigational Drugs.
17:1225-1235.
2008
|
|
| 2008
|
Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expression.
Clinical Cancer Research.
14:4694-4704.
2008
|
|
| 2008
|
Phase i and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
Neuro-Oncology.
10:608-616.
2008
|
|
| 2008
|
Central nervous system cancers.
2008
|
|
| 2008
|
Central nervous system cancers: Clinical Practice Guidelines in Oncology™
2008
|
|
| 2007
|
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
Journal of Clinical Oncology.
25:1651-1657.
2007
|
|
| 2007
|
ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
Cancer Biology and Therapy.
6:454-462.
2007
|
|
| 2006
|
Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).
Journal of Neuro-Oncology.
80:261-274.
2006
|
|
| 2006
|
1p/19q chromosome deletions in metastatic oligodendroglioma.
Journal of Neuro-Oncology.
80:203-207.
2006
|
|
| 2006
|
Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy
2006
|
|
| 2006
|
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
Journal of Clinical Oncology.
24:3644-3650.
2006
|
|
| 2006
|
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177
2006
|
|
| 2006
|
Phase I trial of bortezomib in adults with recurrent malignant glioma..
Journal of Clinical Oncology.
24:1567.
2006
|
|
| 2006
|
Safety and tolerance of multiple weekly intracavitary injections of 131I-chlorotoxin (TM-601): Preliminary results of a prospective clinical trial in patients with recurrent glioblastoma multiforme..
Journal of Clinical Oncology.
24:1555.
2006
|
|
| 2006
|
A novel technique to quantify glioma tumor invasion using serial microscopy sections.
Journal of Neuroscience Methods.
153:183-189.
2006
|
|
| 2005
|
The ELAV RNA-stability factor HuR binds the 5′-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation.
Nucleic Acids Research.
33:2962-2979.
2005
|
|
| 2005
|
Lyn kinase activity is the predominant cellular Src kinase activity in glioblastoma tumor cells.
Cancer Research.
65:5535-5543.
2005
|
|
| 2005
|
Treatment of adults with recurrent malignant glioma
2005
|
|
| 2005
|
IL-1β induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3′ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR.
International Journal of Cancer.
113:911-919.
2005
|
|
| 2004
|
Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trial.
Journal of Magnetic Resonance Imaging.
20:913-922.
2004
|
|
| 2004
|
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.
Molecular Therapy.
10:958-966.
2004
|
|
| 2004
|
Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Clinical Cancer Research.
10:5643-5646.
2004
|
|
| 2004
|
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11.
Neuro-Oncology.
6:21-27.
2004
|
|
| 2004
|
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11..
Neuro-Oncology.
6:21-27.
2004
|
|
| 2004
|
Prognostic Value of 1p, 19q, 9p, 10q, and EGFR-FISH Analyses in Recurrent Oligodendrogliomas.
Journal of Neuropathology and Experimental Neurology.
63:314-322.
2004
|
|
| 2004
|
Targeted molecular therapy for malignant gliomas.
Current Treatment Options in Oncology.
5:519-526.
2004
|
|
| 2003
|
Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuR.
Cancer Research.
63:4181-4187.
2003
|
|
| 2002
|
Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation.
Molecular Cancer Therapeutics.
1:1139-1145.
2002
|
|
| 2002
|
Human cytomegalovirus infection and expression in human malignant glioma.
Cancer Research.
62:3347-3350.
2002
|
|
| 2001
|
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells..
Journal of Clinical Investigation.
108:1657-1665.
2001
|
|
| 2001
|
HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAs.
Cancer Research.
61:2154-2161.
2001
|
|
| 2001
|
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.
Journal of Clinical Investigation.
108:1657-1665.
2001
|
|
| 2000
|
Analysis of the 5' end of the mouse Elavl1 (mHuA) gene reveals a transcriptional regulatory element and evidence for conserved genomic organization.
Gene.
242:125-131.
2000
|
|
| 1999
|
Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease.
Journal of Autoimmunity.
13:435-443.
1999
|
|
| 1998
|
HuR, a novel target of anti-Hu antibodies, is expressed in non-neural tissues.
Journal of Neuroimmunology.
92:152-159.
1998
|
|
| 1997
|
Magnetic resonance cisternography in the diagnosis of delayed iatrogenic cerebrospinal fistula: A case report.
Journal of Neuroimaging.
7:244-247.
1997
|
|
| 1991
|
A unique neuronal organization in the cat pretectum revealed by antibodies to the calcium-binding protein calbindin-D 28K
1991
|
|
| 1988
|
Quantitative immunocytochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysis.
Journal of Neuroscience Methods.
26:1-23.
1988
|
|
| 1988
|
Quantitative immunocytochemistry using an image analyzer. II. Concentration standards for transmitter immunocytochemistry.
Journal of Neuroscience Methods.
26:25-34.
1988
|
|
